Sugi Predict

Sugi Predict / Compounds / SCHEMBL20553287

SCHEMBL20553287

SCHEMBL20553287

CC1(C)OB(c2cnc(NCC#C[Si](C)(C)C)nc2)OC1(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.38
▸ DGAT1 O75907 2/20 0.36
▸ LPL P06858 7/20 0.34
▸ LIPG Q9Y5X9 7/20 0.34
▸ GSK3A P49840 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ ROCK2 O75116 1/20 0.32
▸ ESR2 Q92731 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31
▸ PDGFRB P09619 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2067804 0.81 LPL (0.45) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL20553330 0.78 DGAT1 (0.36) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL19949163 0.77 FFAR1 (0.41) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL17800126 0.76 DGAT1 (0.41) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL20329673 0.75 DGAT1 (0.39) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL336629 0.75 FFAR1 (0.41) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL1841804 0.75 DGAT1 (0.43) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL1842384 0.75 DGAT1 (0.41) FFAR1DGAT1LPLLIPGGSK3A
SCHEMBL17800073 0.75 DGAT1 (0.49) DGAT1LPLLIPGPDGFRBKDR
SCHEMBL31217419 0.75 FFAR1 (0.37) FFAR1DGAT1LPLLIPGGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2023-03-30 — — US disclosed
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2021-04-01 — — US disclosed
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. 2021-04-01 — — US disclosed
EP-3619216-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2020-03-11 — — EP disclosed
CN-110770243-A Rapamycin analogs as MTOR inhibitors 锐新医药公司 2020-02-07 — — CN disclosed
WO-2018204416-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2018-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230093861-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR FFAR1 3284/4885DGAT1 2037/4885LPL 1878/4885
US-20210094975-A1 RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR FFAR1 3284/4885DGAT1 2037/4885LPL 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.